Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ETON Eton Pharmaceuticals	$15.10 +8.2%	$16.18	$3.25 ▼ $21.48	$404.98M	1.18	365,933 shs	155,616 shs
RAPP Rapport Therapeutics	$15.07 +1.5%	$11.59	$6.43 ▼ $29.74	$548.05M	N/A	165,751 shs	37,637 shs
RVNC Revance Therapeutics	$3.65	$3.65	$2.76 ▼ $6.65	$381.02M	0.9	3.73 million shs	N/A
SLN Silence Therapeutics	$6.06 -2.6%	$5.44	$1.97 ▼ $22.47	N/A	1.39	227,283 shs	21,111 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ETON Eton Pharmaceuticals	+0.43%	-10.35%	+2.50%	-2.72%	+288.58%
RAPP Rapport Therapeutics	-2.50%	-3.51%	+35.53%	+46.21%	-43.25%
RVNC Revance Therapeutics	0.00%	0.00%	0.00%	0.00%	-7.83%
SLN Silence Therapeutics	-2.05%	-3.12%	+15.83%	+98.09%	-69.54%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ETON Eton Pharmaceuticals	1.9709 of 5 stars	3.5	1.0	0.0	1.9	1.7	0.6
RAPP Rapport Therapeutics	1.4283 of 5 stars	3.5	0.0	0.0	1.7	0.8	0.6
RVNC Revance Therapeutics	2.6704 of 5 stars	3.1	0.0	4.7	0.0	1.7	0.6
SLN Silence Therapeutics	1.7331 of 5 stars	3.4	1.0	0.0	1.5	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ETON Eton Pharmaceuticals	3.00	Buy	$29.67	96.47% Upside
RAPP Rapport Therapeutics	3.00	Buy	$28.00	85.86% Upside
RVNC Revance Therapeutics	2.13	Hold	$8.45	131.51% Upside
SLN Silence Therapeutics	2.71	Moderate Buy	$33.83	458.31% Upside

Current Analyst Ratings Breakdown

Latest SLN, ETON, RVNC, and RAPP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	RAPP Rapport Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$28.00
6/13/2025	SLN Silence Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
6/13/2025	SLN Silence Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00
5/29/2025	ETON Eton Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $35.00
5/16/2025	ETON Eton Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $26.00
5/14/2025	ETON Eton Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$26.00 ➝ $28.00
5/9/2025	SLN Silence Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$4.00 ➝ $3.00
5/9/2025	SLN Silence Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $25.00
5/9/2025	SLN Silence Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $35.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ETON Eton Pharmaceuticals	$39.01M	10.38	N/A	N/A	$0.94 per share	16.06
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	$8.35 per share	N/A
RVNC Revance Therapeutics	$234.04M	1.63	N/A	N/A	($1.73) per share	-2.11
SLN Silence Therapeutics	$43.26M	N/A	N/A	N/A	$4.48 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ETON Eton Pharmaceuticals	-$3.82M	-$0.18	N/A	30.20	N/A	-9.49%	-3.15%	-1.08%	8/4/2025 (Estimated)
RAPP Rapport Therapeutics	-$78.31M	-$3.45	N/A	N/A	N/A	N/A	-25.48%	-24.63%	8/14/2025 (Estimated)
RVNC Revance Therapeutics	-$323.99M	-$1.93	N/A	N/A	N/A	-74.67%	N/A	-37.22%	8/6/2025 (Estimated)
SLN Silence Therapeutics	-$45.31M	-$1.50	N/A	N/A	N/A	-260.55%	-56.17%	-33.96%	8/21/2025 (Estimated)

Latest SLN, ETON, RVNC, and RAPP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/15/2025	Q2 2025	SLN Silence Therapeutics	-$0.2067	N/A	N/A	N/A	$3.38 million	N/A
8/14/2025	Q2 2025	ETON Eton Pharmaceuticals	-$0.02	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	RAPP Rapport Therapeutics	-$0.87	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	ETON Eton Pharmaceuticals	$0.09	$0.07	-$0.02	-$0.06	$14.33 million	$17.28 million
5/8/2025	Q1 2025	RAPP Rapport Therapeutics	-$0.77	-$0.68	+$0.09	-$0.68	N/A	N/A
5/8/2025	Q1 2025	SLN Silence Therapeutics	-$0.18	-$0.60	-$0.42	-$0.60	$3.58 million	$0.14 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	N/A
RVNC Revance Therapeutics	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ETON Eton Pharmaceuticals	1.23	1.97	1.43
RAPP Rapport Therapeutics	N/A	31.01	31.01
RVNC Revance Therapeutics	N/A	4.12	3.05
SLN Silence Therapeutics	N/A	8.81	8.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ETON Eton Pharmaceuticals	27.86%
RAPP Rapport Therapeutics	N/A
RVNC Revance Therapeutics	97.70%
SLN Silence Therapeutics	98.73%

Insider Ownership

Company	Insider Ownership
ETON Eton Pharmaceuticals	16.03%
RAPP Rapport Therapeutics	N/A
RVNC Revance Therapeutics	5.10%
SLN Silence Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ETON Eton Pharmaceuticals	20	26.82 million	22.52 million	Optionable
RAPP Rapport Therapeutics	N/A	36.50 million	N/A	N/A
RVNC Revance Therapeutics	500	104.39 million	99.07 million	Optionable
SLN Silence Therapeutics	100	N/A	N/A	Not Optionable

SLN, ETON, RVNC, and RAPP Headlines

Recent News About These Companies

Silence Therapeutics (NASDAQ:SLN) Stock Rating Lowered by Wall Street Zen

July 14, 2025 | americanbankingnews.com

Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera

June 12, 2025 | businesswire.com

Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet

June 6, 2025 | zacks.com

Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade

May 21, 2025 | zacks.com

Silence Therapeutics plc GAAP EPS of -C$0.20

May 8, 2025 | seekingalpha.com

Silence Therapeutics plc: Silence Therapeutics Welcomes Tim McInerney to Board of Directors

May 6, 2025 | finanznachrichten.de

Silence Therapeutics Welcomes Tim McInerney to Board of Directors

May 6, 2025 | businesswire.com

Silence Therapeutics plc (SLN): Among Takeover Rumors Hedge Funds Are Buying

April 23, 2025 | insidermonkey.com

Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

March 5, 2025 | businesswire.com

Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know

March 4, 2025 | zacks.com

Silence Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

March 1, 2025 | uk.finance.yahoo.com

Silence Therapeutics plc (SLN) Q4 2024 Earnings Call Transcript

February 28, 2025 | seekingalpha.com

Silence Quiets Phase III Pace for Lipoprotein Drug, Seeks Partner

February 28, 2025 | biospace.comB

Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

February 27, 2025 | businesswire.com

Goldman Sachs Initiates Coverage of Silence Therapeutics plc - Depositary Receipt () (SLN) with Sell Recommendation

February 11, 2025 | msn.com

Silence Therapeutics hit with new Sell at Goldman Sachs on resource constraints

February 11, 2025 | seekingalpha.com

Goldman starts Silence Therapeutics at Sell on ‘undifferentiated’ data

February 11, 2025 | markets.businessinsider.com

Silence Therapeutics initiated with a Sell at Goldman Sachs

February 11, 2025 | markets.businessinsider.com

Goldman Sachs cuts Silence Therapeutics stock rating to Sell

February 11, 2025 | msn.com

(SLN) Investment Analysis

January 17, 2025 | news.stocktradersdaily.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLN, ETON, RVNC, and RAPP Company Descriptions

Eton Pharmaceuticals NASDAQ:ETON

$15.10 +1.15 (+8.24%)

As of 12:24 PM Eastern

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Rapport Therapeutics NASDAQ:RAPP

$15.06 +0.23 (+1.52%)

As of 12:24 PM Eastern

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

Revance Therapeutics NASDAQ:RVNC

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Silence Therapeutics NASDAQ:SLN

$6.06 -0.16 (-2.57%)

As of 12:24 PM Eastern

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time